FDA 483 - Apnar Pharma Private Limited - September 16, 2022

An FDA inspection of Apnar Pharma Private Limited in Vadodara, India, revealed a significant data integrity concern. The firm failed to exercise appropriate controls over computer systems, specifically noting that the FTIR instrument's software lacked audit trail capability. This deficiency impacts the identity testing of finished products and components, indicating a serious lapse in quality control.